Two regimens of intravitreal Conbercept improve outcomes in polypoidal choroidal vasculopathy: STAR study.

A new study found that both the fixed dosing regimen and the treat-and-extend regimen of intravitreal conbercept (IVC) resulted in improvement in visual and anatomical outcomes in polypoidal choroidal vasculopathy (PCV) patients. The study results were published in the journal Acta Ophthalmologica. 

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (nAMD). Out of the multiple therapeutic options, available Conbercept is a novel fusion protein used for the management of nAMD. Previous literature has shown the efficacy of conbercept in nAMD but there is meager information on the optimal treatment strategy for use in clinical practice. Hence researchers conducted a multicenter, parallel, open-label, randomized clinical trial in 32 eye centers in China to compare the efficacy and safety of two different treatment regimens of IVC for PCV. 

249 patients who are treatment naïve with PCV were randomized 1:1 to two groups. They are the fixed dosing regimen group with injections given every 12 weeks (3 + Q12W) and the treat-and-extend regimen (3 + TAE) group. A loading dose of 3 monthly 0.5 mg intravitreal injections of conbercept was given to patients as a loading dose in both groups. The 3 + Q12W patients were monitored monthly and received mandated injections every 12 weeks; the 3 + TAE patients were monitored and treated monthly until the resolution of exudative disease activity. The interval between visits was then individualized according to the study protocol. Visual and anatomical outcomes were compared between the two groups.